Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 5/20 | 0.33 |
| ▸ | SSTR1 | P30872 | 3/20 | 0.33 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16095512 | 0.82 | BTK (0.42) | BTKGAAEPHX2SSTR4SSTR1 | |
| SCHEMBL4364904 | 0.78 | BTK (0.42) | BTKGAAEPHX2SSTR4SSTR1 | |
| SCHEMBL4359773 | 0.78 | BTK (0.42) | BTKGAAEPHX2SSTR4SSTR1 | |
| SCHEMBL4359769 | 0.78 | BTK (0.42) | BTKGAAEPHX2SSTR4SSTR1 | |
| SCHEMBL14923688 | 0.78 | BTK (0.42) | BTKGAAEPHX2SSTR4SSTR1 | |
| SCHEMBL4364906 | 0.78 | BTK (0.42) | BTKGAAEPHX2SSTR4SSTR1 | |
| SCHEMBL4369929 | 0.78 | SSTR4 (0.49) | BTKGAAEPHX2SSTR4SSTR1 | |
| SCHEMBL4365082 | 0.78 | SSTR4 (0.49) | BTKGAAEPHX2SSTR4SSTR1 | |
| SCHEMBL4365093 | 0.78 | SSTR4 (0.49) | BTKGAAEPHX2SSTR4SSTR1 | |
| SCHEMBL4369925 | 0.78 | SSTR4 (0.49) | BTKGAAEPHX2SSTR4SSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970340-B1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS INC (US) | 2020-02-12 | — | — | EP | disclosed |
| US-10294248-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20180273552-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH | 2018-09-27 | — | — | US | disclosed |
| US-9944658-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160024121-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. | 2016-01-28 | — | — | US | disclosed |
| EP-2970340-A1 | BETA-LACTAMASE INHIBITORS | Venatorx Pharmaceuticals Inc (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014151958-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273552-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | BTK 524/4885GAA 2/4885EPHX2 2331/4885 |
| US-10294248-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | BTK 524/4885GAA 2/4885EPHX2 2331/4885 |
| US-20160024121-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | BTK 524/4885GAA 2/4885EPHX2 2331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.